Fibroblast growth factor 21 attenuates hepatic fibrogenesis through TGF-β/smad2/3 and NF-κB signaling pathways

Toxicology and Applied Pharmacology

Volumn 290, Issue , 2016, Pages 43-53

  Xu, Pengfei ^a   Zhang, Yingjie ^a   Liu, Yunye ^a   Yuan, Qingyan ^a   Song, Liying ^a   Liu, Mingyao ^a   Liu, Zhihang ^a   Yang, Yongbi ^a   Li, Junyan ^a   Li, Deshan ^a   Ren, Guiping ^a  

^a NORTHEAST AGRICULTURAL UNIVERSITY   (China)

Author keywords

Fibroblast growth factor 21; Hepatic fibrogenesis; Hepatic stellate cells; NF B; TGF

Indexed keywords

ALCOHOL; ALPHA SMOOTH MUSCLE ACTIN; ANTIFIBROTIC AGENT; CASPASE 3; COLLAGEN TYPE 1; CYTOKINE; DIMETHYLNITROSAMINE; FIBROBLAST GROWTH FACTOR 21; HYDROXYPROLINE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BAX; PROTEIN BCL 2; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; ACTIN; ALPHA-SMOOTH MUSCLE ACTIN, MOUSE; BAX PROTEIN, MOUSE; BCL2 PROTEIN, MOUSE; CASP3 PROTEIN, MOUSE; FIBROBLAST GROWTH FACTOR; SMAD2 PROTEIN, MOUSE; SMAD3 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; FIBROGENESIS; GENE EXPRESSION; HISTOPATHOLOGY; LIVER FIBROSIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; RAT; SIGNAL TRANSDUCTION; STELLATE CELL; ANIMAL; APOPTOSIS; DOWN REGULATION; DRUG EFFECTS; GENETICS; INSTITUTE FOR CANCER RESEARCH MOUSE; LIVER; LIVER CIRRHOSIS; MALE; METABOLISM; PATHOLOGY;

ACTINS; ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; COLLAGEN TYPE I; DIMETHYLNITROSAMINE; DOWN-REGULATION; FIBROBLAST GROWTH FACTORS; HEPATIC STELLATE CELLS; HYDROXYPROLINE; LIVER; LIVER CIRRHOSIS; MALE; MICE; MICE, INBRED ICR; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84948425213     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2015.11.012     Document Type: Article

References (55)

1. Szuster-Ciesielska A., Mizerska-Dudka M., et al. Butein inhibits ethanol-induced activation of liver stellate cells through TGF-β, NF-κB, p38, and JNK signaling pathways and inhibition of oxidative stress. J. Gastroenterol. 2013, 48:222-237.
2. Bataller R., Brenner D.A. Liver fibrosis. J. Clin. Invest. 2005, 115:209-218.
3. Bauer M., Schuppan D. TGFbeta1 in liver fibrosis: time to change paradigms. FEBS Lett. 2001, 502:1-3.
4. Carpino G., Morini S., et al. AlphaSMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation. Dig. Liver Dis. 2005, 37:349-356.
5. Chor J.S., Yu J., Chan K.K., Go Y.Y., Sung J.J. Stephania tetrandra prevents and regresses liver fibrosis induced by carbon tetrachloride in rats. J. Gastroenterol. Hepatol. 2009, 24:853-859.
6. Clouthier D.E., Comerfod S.A., Hammer R.E. Hepatic fibrosis, glomerulosclerosis, and lipodystrophy-like syndrome in PEPCK-TGF-beta1 transgenic mice. J. Clin. Invest. 2000, 100:2697-2713.
7. Coulouarn C., Clement B. Stellate cells and the development of liver cancer: therapeutic potential of targeting the stroma 2014, J Hepatol.
8. Dushay J., Chui P.C., Gopalakrishnan G.S., et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010, 139(2):456-463.
9. Freidman S.L. The cellular basis of hepatic fibrosis. New Engl. J. Med 1993, 328:1828-1835.
10. Friedman S.L. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008, 134:1655-1669.
11. Friedman S.L. Liver fibrosis - from bench to bedside. J. Hepatol. 2003, 38(Suppl.1):S38-S53.
12. Friedman S.L., Yamasaki G., Wong L. Modulation of transforming growth factor beta receptors of rat lipocytes during the hepatic wound healing response. Enhanced binding and reduced gene expression accompany cellular activation in culture and in vivo. J. Biol. Chem. 1994, 269:10551-10558.
13. Gentilini A., Lottini B., Brogi M., Caligiuri A., Cosmi L., Marra F., et al. Evaluation of intracellular signalling pathways in response to insulin-like growth factor I in apoptotic-resistant activated human hepatic stellate cells. Fibrogenesis Tissue Repair 2009, 2:1.
14. George J., Chandrakasan G. Molecular characteristics of dimethylnitrosamine-induced fibrotic liver collagen. Biochim. Biophys. Acta 1996, 1292:215-222.
15. Ghosh S., Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002, 109:S81-S96. (Suppl.).
16. Gressner A.M., Weiskirchen R., Breitkopf K., Dooley S. Roles of TGF-beta in hepatic fibrosis. Front. Biosci. 2002, 7:d793-d807.
17. Guo J., Friedman S.L. Hepatic fibrogenesis. Semin. Liver Dis. 2007, 27:413-426.
18. Hellerbrand C., Jobin C., Limuro Y., Licato L., Sartor R.B., Brenner D.A. Inhibition of NF-kappa B in activated rat hepatic stellate cells by proteasome inhibitors and an I-kappa B super-repressor. Hepatology 1998, 27:1285-1295.
19. Choi H.-K., Pokharel Y.R., Lim S.C., Han H.-K., Ryu C.S., Kim S.K., Kwak M.K., Kang K.W. Toxicol. Appl. Pharmacol. 2009, 240:377-384.
20. Iredale J.P., Benyon R.C., Pickering J., McCullen M., Northrop M., Pawley S., et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J. Clin. Invest. 1998, 102:538-549.
21. Itoh N., Ornitz D.M. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J. Biochem. 2011, 149:121-130.
22. Jin Y.L., Enzan H., Kuroda N., Hayashi Y., Nakayama H., Zhang Y.H., et al. Tissue remodeling following submassive hemorrhagic necrosis in rat livers induced by an intraperitoneal injection of dimethylnitrosamine. Virchows Arch. 2003, 442:39-47.
23. Lee J.-H., Lee H., et al. The use of low molecular weight heparinepluronic nanogels to impede liver fibrosis by inhibition the TGF-β/Smad signaling pathway. Biomaterials 2011, 32:1438-1445.
24. Karin M., Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-(kappa)B activity. Annu. Rev. Immunol. 2000, 18:621-663.
25. Katsunoriyoshida M., et al. TGF-β/Smad signaling during hepatic fibro-carcinogenesis (review). Int. J. Oncol. 2014, 45:1363-1371.
26. Kharitonenkov A., Shiyanova T.L., Koester A., Ford A.M., Micanovic R., et al. FGF-21 as a novel metabolic regulator. J. Clin. Invest. 2005, 115:1627-1635.
27. Kharitonenkov A., Wroblewski V.J., Koester A., Chen Y.F., Clutinger C.K., et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007, 148(2):774-781.
28. Kaji K., Yoshiji H., et al. Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats. J. Gastroenterol. 2014, 49:481-491.
29. Kweon Y.O., Paik Y.H., Schnabl B., Qian T., Lemaster J.J., Brenner D.A. Gliotoxin-mediated apoptosis of activated human hepatic stellate cells. J. Hepatol. 2003, 39:38-46.
30. Lee Y., Lim S., Hong E.S., et al. Serum FGF21 concentration is associated with hypertriglyceridaemia, hyperinsulinaemia and pericardial fat accumulation, independently of obesity, but not with current coronary artery status[J]. Clin. Endocrinol. 2014, 80(1):57-64.
31. Mencin A., Kluwe J., Schwabe R.F. Toll-like receptors as targets in chronic liver diseases. Gut 2009, 58:704-720.
32. Novo E., Marra F., Zamara E., Valfre di Bonzo L., Monitillo L., Cannito S., et al. Overexpression of Bcl-2 by activated human hepatic stellate cells: resistance to apoptosis as a mechanism of progressive hepatic fibrogenesis in humans. Gut 2006, 55:1174-1182.
33. Oakley F., et al. Angiotensin II activates I kappaB kinase phosphorylation of RelA at Ser 536 to promote myofibroblast survival and liver fibrosis. Gastroenterology 2009, 136:2334-2344.e1.
34. Oakley F., Meso M., Iredale J.P., Green K., Marek C.J., et al. Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis. Gastroenterology 2005, 128:108-120.
35. Parola M., Marra F., Pinzani M. Myofibroblast-like cells and liver fibrogenesis: emerging concepts in a rapidly moving scenario. Mol. Asp. Med. 2008, 29:58-66.
36. Parsons C.J., Takashima M., Rippe R.A. Molecular mechanisms of hepatic fibrogenesis. J. Gastroenterol. Hepatol. 2007, 22(Suppl. 1):S79-S84.
37. Peng Z., Borea P.A., Varani K., Wilder T., Yee H., et al. Adenosine signaling contributes to ethanol-induced fatty liver in mice. J. Clin. Invest. 2009, 119:582-594.
38. Pinzani M., Marra F., Carloni V. Signal transduction in hepatic stellate cells. Liver 1998, 18:2-13.
39. Potthoff M.J., Inagaki T., et al. FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:10853-10858.
40. Qi Z., Atsuchi N., Ooshima A., Takeshita A., Ueno H. Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat. Proc. Natl. Acad. U.S.A. 1999, 96:2345-2349.
41. Reinehr T., Woelfle J., Wunsch R., et al. Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis. J. Clin. Endocrinol. Metab. 2012, 97(6):2143-2150.
42. Schuppan D., Kim Y.O. Evolving therapies for liver fibrosis. J. Clin. Invest. 2013, 123:1887-1901.
43. Luedde T., Schwabe R.F. NF-κB in the liver-linking injury, fibrosis and hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 2011 February, 8(2):108-118.
44. Toyoki Y., Sasaki M., Narumi S., Yoshihara S., Morita T., Konn M. Semiquantitative evaluation of hepatic fibrosis by measuring tissue hydroxyproline. Hepato-Gastroenterology 1998, 45:2261-2264.
45. Wasmuth H.E., Tacke F., Trautwein C. Chemokines in liver inflammation and fibrosis. Semin. Liver Dis. 2010, 30:215-225.
46. Wright M.C., Issa R., Smart D.E., Trim N., Murray G.I., Primrose J.N., et al. Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology 2001, 121:685-698.
47. Xavier S., Piek E., Fujii M., Javelaud D., Mauviel A., Flanders K.C., et al. Amelioration of radiation-induced fibrosis: inhibition of transforming growth factor-beta signaling by halofuginone. J. Biol. Chem. 2004, 279(15):15167-15176.
48. Xiao C., Ghosh S. NF-kappaB, an evolutionarily conserved mediator of immune and inflammatory responses. Adv. Exp. Med. Biol. 2005, 560:41-45.
49. Xiao Y., Xu A., Law L.S.C., et al. Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes. J. Clin. Endocrinol. Metab. 2011.
50. Xu J., Lloyd D.J., Hale C., Stanislaus S., Chen M., et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009, 58:250-259.
51. Wang Y., Gao J., et al. New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. J. Hepatol. 2010, 53:132-144.
52. Yang X., Letterio J.J., Lechleider R.J., Chen L., Hayman R., Gu H., et al. Targeted disruption of SMAD 3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J 1999, 18(5):1280-1291.
53. Ye D., Wang Y., Li H., et al. FGF21 protects against acetaminophen-induced hepatotoxicity by potentiating PGC-1alpha-mediated antioxidant capacity in mice. Hepatology 2014, 60:977-989.
54. Yu Y., Bai F., et al. Fibroblast growth factor (FGF21) protects mouse liver against D-galactose-induced oxidative stress and apoptosis via activating Nrf2 and PI3K/Akt pathways. Mol. Cell. Biochem. 2015 Feb, 21.
55. Yu J., Wu C.W., Hui A.Y., et al. Elucidation of the role of COX-2 in liver fibrogenesis using transgenic mice. Biochem. Biophys. Res. Commun. 2008, 372:571-577.